Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Options Markets Have Priced In A Modest Pull-Back Of SPY This Week

2018-07-15 seekingalpha
The SPX and VIX options markets have priced in a modest pull-back for SPY this week.

SPX to Report Second Quarter 2018 Financial Results on August 2nd

2018-07-12 globenewswire
CHARLOTTE, N.C., July 12, 2018 (GLOBE NEWSWIRE) -- SPX Corporation (NYSE:SPXC) announced today that it will release its second quarter 2018 financial results after market close on Thursday, August 2, 2018.

SPX to Exit Heat Transfer Business

2018-07-02 globenewswire
Selling Brands and Technology to Godrej & Boyce Manufacturing Co Ltd Updating 2018 Guidance for Impact

Stock Markets Hyper-Risky 3

2018-06-30 seekingalpha
Today’s euphoric stock markets remain hyper-risky. They are still trading at dangerous bubble valuations despite the largest corporate tax cuts in US history!

SPX to Participate in CJS Securities 18th Annual “New Ideas” Summer Conference

2018-06-25 globenewswire
CHARLOTTE, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- SPX Corporation (NYSE:SPXC) announced today that Gene Lowe, President and Chief Executive Officer, and Paul Clegg, Vice President Investor Relations and Communications, will participate in the CJS Securities 18th Annual “New Ideas” Summer Conference in White Plains, NY, on Tuesday, July 10, 2018.

5 Stocks to Check Out Before You Go Away in May

2018-05-10 marketrealist
The S&P 500 (SPY) has bounced nicely off its low of 2595 a week ago. The SPX is up 5% since then, a nice higher low than we saw in early April. Overall the market has been range bound since October of last year. Volatility is low, but the summer is coming. And as I wrote about yesterday, there are some worries out there: Netflix and Chill? So what to do? Tough to just sled along passively. So we found five new stocks to watch.

SPX Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by SPX Corporation in conjunction with their 2018 Q1 earnings call.

SPX Reports First Quarter 2018 Results

2018-05-03 globenewswire
Q1 GAAP EPS of $0.28; Adjusted EPS* of $0.44 Solid Growth in HVAC and Detection & Measurement On Track to Achieve Full-Year Adjusted EPS* Guidance Range of $2.03-$2.18

SPX Announces Agreement to Purchase CUES, Inc.

2018-04-23 globenewswire
Highly Complementary Transaction Expected to Close in Q2 2018; Substantially Strengthens SPX’s Global Position in Pipe Inspection Equipment; Expected to be Modestly Accretive to 2018 Adjusted EPS* Guidance

Short-Term Market Signals

2018-03-30 seekingalpha
We reviewed the daily charts after yesterday's close and noticed that the Russell 2000 Index, the NYA and transportation stocks all exhibited relative strength (the same holds actually for the DJIA), particularly versus the FANG/NDX group. This is happening just as the SPX is battling with an extremely important trend line. As we pointed out before, relative strength in the RUT in particular served as a short-term reversal signal ever since the sell-off started in February.

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 784635104